Wells Fargo Maintains Overweight on Merck & Co, Lowers Price Target to $145

Benzinga Newsdesk www.benzinga.com Negative 77.0%

Neg 77% Neu 0% Pos 0%

Wells Fargo analyst Mohit Bansal maintains Merck & Co (NYSE:MRK) with a Overweight and lowers the price target from $150 to $145.